MedTrace Logo

A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

NCT07570758 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-05-08

No results posted yet for this study

Summary

The primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.

Conditions

  • Obesity & Overweight

Interventions

DRUG

ERX1000

2mg tablet administered orally twice weekly.

OTHER

Placebo

2mg Placebo tablet identical in appearance to 2mg ERX1000 tablet

Sponsors & Collaborators

  • ERX Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07570758 on ClinicalTrials.gov